cholangiocarcinoma, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, cholangiocarcinoma

Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM 2006 Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am. J. Surg. Pathol. 30: 1454-1461.
Abu Al-Soud W, Stenram U, Ljungh A, Tranberg KG, Nilsson HO, Wadstrom T 2008 DNA of Helicobacter spp. and common gut bacteria in primary liver carcinoma. Dig. Liver Dis. 40: 126-131.
Abu-Elmagd KM, Malinchoc M, Dickson ER, Fung JJ, Murtaugh PA, Langworthy AL, Demetris AJ, Krom RA, Van Thiel DH, Starzl TE 1993 Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg. Gynecol. Obstet. 177: 335-344.
Abu-Hamda EM, Baron TH 2004 Endoscopic management of cholangiocarcinoma. Semin. Liver Dis. 24: 165-175.
Agustsson AI, Cariglia N 2007 Caroli's disease, case report and review of the literature. Laeknabladid 93: 603-605.
Ahmad J, Slivka A 2002 Hepatobiliary disease in inflammatory bowel disease. Gastroenterol. Clin. North Am. 31: 329-345.
Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, Sidransky D 1999 Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J. Surg. Res. 84: 88-93. *
Ahrendt SA, Nakeeb A, Pitt HA 2001 Cholangiocarcinoma. Clin. Liver Dis. 5: 191-218.
Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, Coleman J, Lillemoe KD, Cameron JL 1998 Primary sclerosing cholangitis: resect, dilate, or transplant? Ann. Surg. 227: 412-423. *
Ahrendt SA, Pitt HA, Nakeeb A, Klein AS, Lillemoe KD, Kalloo AN, Cameron JL 1999 Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J. Gastrointest. Surg. 3: 357-367.
Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D 2000 p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J. Hepatobiliary Pancreat. Surg. 7: 426-431.
Alba LM, Angulo P, Lindor KD 2002 Primary sclerosing cholangitis. Minerva Gastroenterol. Dietol. 48: 99-113.
Alberti-Flor JJ, Avant GR, Dunn GD 1985 Primary sclerosing cholangitis. South. Med. J. 78: 173-177.
Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T 2008 Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. Jun 18 [Epub ahead of print].
Alfke H, Alfke B, Froelich JJ, Klose KJ, Wagner HJ 2003 Treatment of malignant biliary occlusion by means of transhepatic percutaneous biliary drainage with insertion of metal stents--results of an 8-year follow-up and analysis of the prognostic parameters. Rofo. 175: 1125-1129.
Alpini G, Kanno N, Phinizy JL, Glaser S, Francis H, Taffetani S, LeSage G 2004 Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G973-G982. *
Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, Onetti Muda A, Dostal DE, De Santis A, Attili AF, Benedetti A, Gaudio E 2006 Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am. J. Pathol. 169: 877-888. *
Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, Corradini SG, Invernizzi P, Franchitto A, Attili AF, Gaudio E, Benedetti A 2007 Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann. Intern. Med. 147: 451-459.
Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D 2004 Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg. 8: 90-97.
Ang TL, Teo EK, Fock KM 2007 Endosonography- vs. endoscopic retrograde cholangiopancreatography-based strategies in the evaluation of suspected common bile duct stones in patients with normal transabdominal imaging. Aliment. Pharmacol. Ther. 26: 1163-1170. *
Angulo P, Lindor KD 1999 Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570. *
Asakura H, Ohtsuka M, Ito H, Kimura F, Ambiru S, Shimizu H, Togawa A, Yoshidome H, Kato A, Miyazaki M 2005 Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology 52: 722-724.
Aust S, Obrist P, Jaeger W, Klimpfinger M, Tucek G, Wrba F, Penner E, Thalhammer T 2004 Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab. Invest. 84: 1024-1036. *
Awadallah NS, Chen YK, Piraka C, Antillon MR, Shah RJ 2006 Is there a role for cholangioscopy in patients with primary sclerosing cholangitis? Am. J. Gastroenterol. 101: 284-291. *
Axelrod D, Koffron A, Kulik L, Al-Saden P, Mulcahy M, Baker T, Fryer J, Abecassis M 2005 Living donor liver transplant for malignancy. Transplantation 79: 363-366.
Balan V, LaRusso NF 1995 Hepatobiliary disease in inflammatory bowel disease. Gastroenterol. Clin. North Am. 24: 647-669.
Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, Boonla C, Wongkham S 2007 A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 247: 301-308.
Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H 2007 Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J. Gastroenterol. 13: 4458-4466. *
Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
Baron TH, Fleischer DE 2002 Past, present, and future of endoscopic retrograde cholangiopancreatography: perspectives on the National Institutes of Health consensus conference. Mayo Clin. Proc. 77: 407-412. *
Bartsch H, Ohshima H, Pignatelli B, Calmels S 1992 Endogenously formed N-nitroso compounds and nitrosating agents in human cancer etiology. Pharmacogenetics 2: 272-277.
Baskin-Bey ES, Moreno Luna LE, Gores GJ 2006 Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology. J. Hepatol. 45: 476-479. *
Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN 2000 Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod. Pathol. 13: 1265-1268. *
Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA 2008 Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J. Gastrointest. Surg. 12: 117-122. *
Belghiti J 2005 Transplantation for liver tumors. Semin. Oncol. 32: S29-S32.
Ben-Menachem T 2007 Risk factors for cholangiocarcinoma. Eur. J. Gastroenterol. Hepatol. 19: 615-617.
Bergquist A 2001 Cholangiocarcinoma in primary sclerosing cholangitis. Department of Gastroenterology and Hepatology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden. Karolinska University Press. *
Bergquist A 2003 Tumor markers and genetic markers in the diagnosis of bile duct carcinoma. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 91. October 15-16. *
Bergquist A, Broome U 2001 Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract. Res. Clin. Gastroenterol. 15: 643-656. *
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U 2002 Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol. 36: 321-327. *
Bergquist A, Glaumann H, Persson B, Broome U 1998 Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311-316. *
Bergquist A, Glaumann H, Stal P, Wang GS, Broome U 2001 Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J. Intern. Med. 249: 69-75. *
Bergquist A, Said K, Broome U 2007 Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand. J. Gastroenterol. 42: 88-93. *
Bergquist A, Tribukait B, Glaumann H, Broome U 2000 Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J. Hepatol. 33: 873-877. *
Berr F 2004 Photodynamic therapy for cholangiocarcinoma. Semin. Liver Dis. 24: 177-187.
Berr F, Wiedmann M, Mossner J, Tannapfel A, Schmidt F 1999 Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 29: 611-613. *
Berthiaume EP, Wands J 2004 The molecular pathogenesis of cholangiocarcinoma. Semin. Liver Dis. 24: 127-137.
Bettinardi N, Felicetta I, Tomasi PA, Colombo C 2003 Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. Clin. Chem. Lab. Med. 41: 311-316.
Bhatia AS, Mihas AA 2006 Cholestatic liver disease. Recognizing the clinical signs. Postgrad. Med. 119: 67-75, 82.
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benezzato L, Papi C, Meucci G, Riegler G, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F 2006 Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut 55: 228-233. *
Bjornsson E, Angulo P 2007 Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am. J. Gastroenterol. 102: 1677-1682. *
Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, Chapman RW 2002 Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 51: 731-735. *
Bjornsson E, Chapman RW 2003 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275.
Bjornsson E, Kilander A, Olsson R 1999 CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19: 501-508. *
Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R 2004 Dominant strictures in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 502-508. *
Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P 2008 The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134: 975-980. *
Bjoro K, Brandsaeter B, Foss A, Schrumpf E 2006 Liver transplantation in primary sclerosing cholangitis. Semin. Liver Dis. 26: 69-79. *
Blachar A, Federle MP, Brancatelli G 2002 Hepatic capsular retraction: spectrum of benign and malignant etiologies. Abdom. Imaging 27: 690-699. *
Blechacz B, Gores GJ 2008 Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. J. Hepatol. 49: 160-162. *
Blechacz B, Gores GJ 2008 Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321.
Blechacz BR, Gores GJ 2008 Cholangiocarcinoma. Clin. Liver Dis. 12: 131-150.
Blendis L, Halpern Z 2004 An increasing incidence of cholangiocarcinoma: why? Gastroenterology 127: 1008-1009. *
Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E 2002 Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand. J. Gastroenterol. 37: 1205-1211. *
Boberg KM, Jebsen P, Clausen OP, Aabakken L, Brekke I, Schrumpf E 2003 Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation. J. Hepatol. 39: 453. *
Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E 2006 Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J. Hepatol. 45: 568-574. *
Boberg KM, Schrumpf E 2004 Prognosis of autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 81. *
Boberg KM, Schrumpf E 2004 Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59.
Boberg KM, Schrumpf E 2003 Diagnosis and differential diagnosis of primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 59-60. October 15-16. *
Boberg KM, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, Schjolberg A, Spurkland A, Clausen OP 2000 Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J. Hepatol. 32: 374-380. *
Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, Broome U, Chapman R, Olerup O, Pares A, Rosina F, Schrumpf E 2001 The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand. J. Gastroenterol. 36: 886-890. *
Bogert PT, LaRusso NF 2007 Cholangiocyte biology. Curr. Opin. Gastroenterol. 23: 299-305.
Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE 2008 Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 9: 149-158.
Braasch JW 1994 Surgery for sclerosing cholangitis. Curr. Opin. Gen. Surg. 1994: 156-160.
Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Oksanen A, Ericzon B-G, Hockerstedt K, Makisalo H, Kirkegaard P, Friman S, Bjoro K, Schrumpf E 2004 Chemopreventive effect of URSO in primary sclerosing cholangitis? Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 78. June 18-19. *
Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Kirkegaard P, Friman S, Bjoro K 2004 Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J. Hepatol. 40: 815-822. *
Broome U 2004 Long term treatment with ursodeoxycholic acid in patients with primary sclerosing cholangitis (PSC). Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 71. June 18-19. *
Broome U 2005 Clinical concepts in PSC. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 76. *
Broome U, Bergquist A 2003 Hepatocellular carcinoma, cholangiocarcinoma, colon and pancreas carcinoma in patients with primary sclerosing cholangitis. Epidemiology and risk factors. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 89-90. October 15-16. *
Broome U, Eriksson LS 1994 Assessment for liver transplantation in patients with primary sclerosing cholangitis. J. Hepatol. 20: 654-659.
Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R 1994 Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 35: 84-89. *
Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, Lindgren S, Fork FT, Jarnerot G, Olsson R 2002 Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J. Hepatol. 36: 586-589. *
Broome U, Lofberg R, Veress B, Eriksson LS 1995 Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22: 1404-1408.
Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G 1996 Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610-615. *
Brountzos EN, Kelekis AD, Ptohis N, Kotsioumba I, Misiakos E, Perros G, Gouliamos AD 2008 Microcatheter use for difficult percutaneous biliary procedures. Cardiovasc. Intervent. Radiol. Mar 5 [Epub ahead of print].
Brugge WR 2005 Endoscopic techniques to diagnose and manage biliary tumors. J. Clin. Oncol. 23: 4561-4565.
Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ 2002 In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Gastroenterol. 97: 1138-1142. *
Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD 2004 Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 523-526. *
Burgos San Juan L 2008 Cholangiocarcinoma. Rev. Med. Chil. 136: 240-248.
Burt AD 2004 Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355. *
Calculli L, Pezzilli R, Fiscaletti M, Casadei R, Brindisi C, Gavelli G 2008 Exocrine pancreatic function assessed by secretin cholangio-Wirsung magnetic resonance imaging. Hepatobiliary Pancreat. Dis. Int. 7: 192-195.
Caldwell SH, Bickston SJ 2001 Cholangioscopy to screen for cholangiocarcinoma in primary sclerosing cholangitis. Liver Transpl. 7: 380. *
Callea F, Sergi C, Fabbretti G, Brisigotti M, Cozzutto C, Medicina D 1993 Precancerous lesions of the biliary tree. J. Surg. Oncol. Suppl. 3: 131-133.
Campbell WL, Ferris JV, Holbert BL, Thaete FL, Baron RL 1998 Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT, cholangiography, US, and MR imaging. Radiology 207: 41-50. *
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kam I 2008 Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 14: 181-185.
Cathomas G, Renner EL 2000 Liver transplantation and tumors: risk and chance. Schweiz. Med. Wochenschr. 130: 963-968.
Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, Monges G, Belghiti J, Sa Cunha A, Laurent-Puig P, Degott C, Zucman-Rossi J 2004 Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J. Hepatol. 41: 292-298. *
Chahal P, Baron TH, Poterucha JJ, Rosen CB 2007 Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction. Liver Transpl. 13: 1168-1173.
Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H 2000 Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31: 7-11. *
Chang YT, Hsu C, Jeng YM, Chang MC, Wei SC, Wong JM 2007 Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma. J. Gastroenterol. Hepatol. 22: 389-394. *
Chapman RW 2004 High dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 75. June 18-19. *
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Chapman RW 1999 Risk factors for biliary tract carcinogenesis. Ann. Oncol. 10 Suppl. 4: 308-311.
Chazouilleres O 2004 Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope? J. Hepatol. 40: 857-859. *
Chazouilleres O, Corpechot C 2006 Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 248-249. *
Chen CY, Lin XZ, Wu HC, Shiesh SC 2005 The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies. Clin. Biochem. 38: 520-525. *
Chen CY, Tsai WL, Wu HC, Syu MJ, Wu CC, Shiesh SC 2008 Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin. Chim. Acta 390: 82-89. *
Cheng JL, Bruno MJ, Bergman JJ, Rauws EA, Tytgat GN, Huibregtse K 2002 Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest. Endosc. 56: 33-39. *
Cheung MT, Lo IL 2008 IgG4-related sclerosing lymphoplasmacytic pancreatitis and cholangitis mimicking carcinoma of pancreas and Klatskin tumour. ANZ J. Surg. 78: 252-256.
Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, Nakauchi H, Iwama A, Taniguchi H 2007 Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133: 937-950. *
Christensen E 2003 Prognosis of untreated primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 63. October 15-16. *
Clarke JD, Thuluvath PJ 2007 Endoscopic frontiers in the field of hepatology. Minerva Gastroenterol. Dietol. 53: 101-109.
Coatmeur O, Rassiat E, Bonniaud P, Jouve JL, Minello A, Bedenne L, Faivre J, Hillon P 2004 Acute pseudo-angiocholitis due to colonic adenocarcinoma in a man with primary sclerosis cholangitis and ulcerative colitis. Ann. Med. Interne. (Paris) 154: 547-548.
Colle I, Van Vlierberghe H 2003 Diagnosis and therapeutic problems of primary sclerosing cholangitis. Acta Gastroenterol. Belg. 66: 155-159.
Corvera CU, Blumgart LH, Darvishian F, Klimstra DS, Dematteo R, Fong Y, D'Angelica M, Jarnagin WR 2005 Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma. J. Am. Coll. Surg. 201: 862-869. *
Crippin JS 2002 Motion - patients with primary sclerosing cholangitis should undergo early liver transplantation: arguments against the motion. Can. J. Gastroenterol. 16: 700-702.
Cui Y, Konig J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D 2003 Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83: 527-538.
Cullen SN, Chapman RW 2005 Review article: current management of primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 21: 933-948. *
Curley SA 2003 CHAPTER 99. Diagnosis and Management of Biliary Tract Cancer. (http://www.cancer.org/downloads/PUB/DOCS/SECTION29/99.pdf) SECTION 29. Neoplasms of the Alimentary Canal. pp. 1423-1430. *
Curzio M, Bernasconi G, Gullotta R, Ceriani A, Sala G 1985 Association of ulcerative colitis, sclerosing cholangitis and cholangiocarcinoma in a patient with IgA deficiency. Endoscopy 17: 123-125.
Czako L, Takacs T, Morvay Z, Csernay L, Lonovics J 2004 Diagnostic value of secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) after unsuccessful endoscopic retrograde cholangiopancreatography (ERCP). Orv. Hetil. 145: 529-534.
Czako L, Takacs T, Morvay Z, Csernay L, Lonovics J 2004 Diagnostic role of secretin-enhanced MRCP in patients with unsuccessful ERCP. World J. Gastroenterol. 10: 3034-3038. *
Czito BG, Anscher MS, Willett CG 2006 Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 20: 873-884.
Dantas W 2000 Primary sclerosing cholangitis. Rev. Gastroenterol. Peru 20: 270-284.
Das KM 2004 Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294. *
Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, Dickson ER, Krawitt E, Coppel R, Gershwin ME 1992 M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 16: 1128-1136.
de Groen PC 2000 Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? Hepatology 31: 247-248. *
De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ 2000 Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 6: 309-316. *
Dehaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling K 2007 An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum. Pathol. 38: 491-499.
Demarchi B, Bresso F, Novero D, Palestro G, Sapone N, Pellicano R, Bonardi R, Smedile A, Rizzetto M, Astegiano M 2007 Hepatocellular carcinoma complicating primary sclerosing cholangitis in Crohn's disease. A case report. Minerva Gastroenterol. Dietol. 53: 279-283.
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *
Desmet VJ 2003 Histology of autoimmune cholestatic liver diseases. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 25-26. October 15-16. *
Dewitt J, Misra VL, Leblanc JK, McHenry L, Sherman S 2006 EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest. Endosc. 64: 325-333.
Domajnko B, Ahrendt SA 2005 Indications for non-transplant surgery in primary sclerosing cholangitis. HPB (Oxford) 7: 292-297. *
Donaldson PT 2005 Basic concepts in PSC. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 73-75. *
Dubaniewicz A, Dubaniewicz A 2003 Cholangiocarcinoma--bile ducts cancer. Wiad. Lek. 56: 57-60.
Dumas A, Thung SN, Lin CS 1998 Diffuse hyperplasia of the peribiliary glands. Arch. Pathol. Lab. Med. 122: 87-89.
Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR 2008 Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 248: 84-96.
Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE 2002 ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36: 439-450. *
Enjoji M, Nakashima M, Nishi H, Choi I, Oimomi H, Sugimoto R, Kotoh K, Taguchi K, Nakamuta M, Nawata H, Watanabe T 2002 The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. J. Hepatol. 36: 786-792. *
Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T 2004 Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig. Liver Dis. 36: 622-627.
Erdogan D, Kloek JJ, Ten Kate FJ, Rauws EA, Busch OR, Gouma DJ, van Gulik TM 2008 Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. Br. J. Surg. 95: 727-734.
Fan WJ, Wu PH, Zhang L, Huang JH, Zhang FJ, Gu YK, Zhao M, Huang XL, Guo CY 2008 Radiofrequency ablation as a treatment for hilar cholangiocarcinoma. World J. Gastroenterol. 14: 4540-4545. *
Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA 2006 Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66: 6622-6627. *
Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R 1991 Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100: 1710-1717.
Fausa O, Kolmannskog F, Ritland S 1985 The pancreatic ducts in primary biliary cirrhosis and sclerosing cholangitis. Scand. J. Gastroenterol. Suppl. 107: 32-35.
Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Steenbergen WV 2005 Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J. Hepatol. 43: 358-360. *
Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W 2007 Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 52: 3123-3135. *
Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA 1995 CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl. Surg. 1: 94-98.
Fleming KA 2003 Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 92. October 15-16. *
Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP 2001 Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J. Hepatol. 34: 360-365. *
Floreani A, Zancan L, Melis A, Baragiotta A, Chiaramonte M 1999 Primary sclerosing cholangitis (PSC): clinical, laboratory and survival analysis in children and adults. Liver 19: 228-233.
Florin TH, Pandeya N, Radford-Smith GL 2004 Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 53: 973-979. *
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Fritscher-Ravens A, Broering DC, Knoefel WT, Rogiers X, Swain P, Thonke F, Bobrowski C, Topalidis T, Soehendra N 2004 EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am. J. Gastroenterol. 99: 45-51. *
Fu X, Tan L, Liu S, Li H, Chen L, Qin J, Wu M, Wang H 2004 A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics. J. Cancer Res. Clin. Oncol. 130: 514-520. *
Furmanczyk PS, Grieco VS, Agoff SN 2005 Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am. J. Clin. Pathol. 124: 355-360.
Gaing AA, Geders JM, Cohen SA, Siegel JH 1993 Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. Am. J. Gastroenterol. 88: 2000-2008.
Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL 2006 C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J. Gastroenterol. 12: 5495-5500. *
Ghali P, Marotta PJ, Yoshida EM, Bain VG, Marleau D, Peltekian K, Metrakos P, Deschenes M 2005 Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl. 11: 1412-1416. *
Glasbrenner B, Ardan M, Boeck W, Preclik G, Moller P, Adler G 1999 Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 31: 712-717.
Gluskin LE, Payne JA 1983 Cystic dilatation as a radiographic sign of cholangiocarcinoma complicating sclerosing cholangitis. Am. J. Gastroenterol. 78: 661-664.
Goldstein ES, Rubin PH 2003 Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243.
Gores GJ 2003 Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J. Hepatol. 38: 671-673. *
Gores GJ 2000 Early detection and treatment of cholangiocarcinoma. Liver Transpl. 6: S30-S34. *
Gores GJ 2003 A spotlight on cholangiocarcinoma. Gastroenterology 125: 1536-1538. *
Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR 2004 Treatment endpoints for advanced cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 4-5. *
Gores GJ, Nagorney DM, Rosen CB 2007 Cholangiocarcinoma: is transplantation an option? For whom? J. Hepatol. 47: 455-459. *
Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, Stribling RJ, Goldstein LI, Busuttil RW 1997 Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann. Surg. 225: 472-481. *
Gossard AA, Angulo P, Lindor KD 2005 Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am. J. Gastroenterol. 100: 1330-1333. *
Gow PJ, Chapman RW 2000 Liver transplantation for primary sclerosing cholangitis. Liver 20: 97-103. *
Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA 1999 Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30: 1121-1127. *
Grune S, Mullhaupt B, Moradpour D, Munch R, Siegenthaler-Zuber G, Siegenthaler W 1991 Primary sclerosing cholangitis. Dtsch. Med. Wochenschr. 116: 1095-1100.
Guarise A, Venturini S, Faccioli N, Pinali L, Morana G 2006 Role of magnetic resonance in characterising extrahepatic cholangiocarcinomas. Radiol. Med. (Torino) 111: 526-538.
Guettier C 2005 Which stem cells for adult liver? Ann. Pathol. 25: 33-44.
Habior A, Rawa T, Orlowska J, Sankowska M, Lewartowska A, Tilszer A, Pawlak J, Krawczyk M, Butruk E 2002 Association of primary sclerosing cholangitis, ulcerative colitis and coeliac disease in female siblings. Eur. J. Gastroenterol. Hepatol. 14: 787-791.
Hajdu CH, Murakami T, Diflo T, Taouli B, Laser J, Teperman L, Petrovic LM 2007 Intrahepatic portal cavernoma as an indication for liver transplantation. Liver Transpl. 13: 1312-1316.
Hamano H, Kawa S, Uehara T, Ochi Y, Takayama M, Komatsu K, Muraki T, Umino J, Kiyosawa K, Miyagawa S 2005 Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest. Endosc. 62: 152-157. *
Han C, Wu T 2005 Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 280: 24053-24063. *
Harada K, Ohba K, Ozaki S, Isse K, Hirayama T, Wada A, Nakanuma Y 2004 Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatology 40: 925-932. *
Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, Nakanuma Y 2003 Lipopolysaccharide activates nuclear factor-kappaB through Toll-like receptors and related molecules in cultured biliary epithelial cells. Lab. Invest. 83: 1657-1667. *
Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH 1997 Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J. Hepatol. 27: 512-516. *
Harrison PM 1999 Prevention of bile duct cancer in primary sclerosing cholangitis. Ann. Oncol. 10 Suppl. 4: 208-211.
He XS, Zhang S, Zhu XF, Ji Y, Zeng JX, Ma Y, Wang DP, Ju WQ, Wu LW, Li Z, Huang JF 2006 Combined total hepatectomy, orthotopic liver transplantation and pancreatoduodenectomy for irresectable hilar bile duct carcinoma. Zhonghua Wai Ke Za Zhi 44: 302-305.
Heimbach JK 2008 Successful liver transplantation for hilar cholangiocarcinoma. Curr. Opin. Gastroenterol. 24: 384-388.
Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB 2004 Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin. Liver Dis. 24: 201-207.
Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB 2006 Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82: 1703-1707.
Heimbach JK, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, Gores GJ 2004 Transplantation for hilar cholangiocarcinoma. Liver Transpl. 10 Suppl. 10: S65-S68. *
Hendrickx BW, Punt CJ, Boerman OC, Postema EJ, Oosterwijk E, Mavridu A, Corstens FH, Oyen WJ 2006 Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biother. Radiopharm. 21: 263-268.
Heneghan MA, Tuttle-Newhall JE, Suhocki PV, Muir AJ, Morse M, Bornstein JD, Sylvestre PB, Collins B, Kuo PC, Rockey DC 2003 De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am. J. Transplant. 3: 634-638. *
Henke AC, Jensen CS, Cohen MB 2002 Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings. Adv. Anat. Pathol. 9: 301-308.
Hocqueloux L, Gervais A 2000 Cholangiocarcinoma and AIDS-related sclerosing cholangitis. Ann. Intern. Med. 132: 1006-1007. *
Hookey LC, Le Moine O, Deviere J 2005 Use of a temporary plastic stent to facilitate the placement of multiple self-expanding metal stents in malignant biliary hilar strictures. Gastrointest. Endosc. 62: 605-609.
Huang C, Lichtenstein DR 2002 Pancreatic and biliary tract disorders in inflammatory bowel disease. Gastrointest. Endosc. Clin. N. Am. 12: 535-559.
Hubert C, Sempoux C, Berquin A, Deprez P, Jamar F, Gigot JF 2005 Bile duct carcinoid tumors: an uncommon disease but with a good prognosis? Hepatogastroenterology 52: 1042-1047.
Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, Wahren B, Broome U 1999 A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J. Hepatol. 30: 669-673. *
Huo TI, Lee SD, Wu JC 2005 Risk factor analysis for cholangiocarcinoma: limitations of cross-sectional study. Gastroenterology 129: 395. *
Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF 2005 Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology 234: 468-478. *
Hutson DG, Russell E, Levi JU, Jeffers LJ, Reddy KR, Yrizarry JM, Scagnelli T, Sleeman D, Schiff ER, Livingstone AS 2001 Dilatation of biliary strictures through the afferent limb of a Roux-en-Y choledochojejunostomy in patients with sclerosing cholangitis. World J. Surg. 25: 1251-1253. *
Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M 2006 CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br. J. Cancer 95: 532-540. *
Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, Nakanuma Y, Futagawa S, Makuuchi M, Yamaoka Y 2004 Report of the 15th follow-up survey of primary liver cancer. Hepatol. Res. 28: 21-29.
Ishimura N, Bronk SF, Gores GJ 2005 Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 128: 1354-1368. *
Ishimura N, Isomoto H, Bronk SF, Gores GJ 2006 TRAIL induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G129-G136. *
Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ 2005 Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42: 1329-1338. *
Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ 2007 Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132: 384-396. *
Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, Nakanuma Y 2005 Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 41: 506-516. *
Jaeckel E, Manns MP 2003 The role of autoantigens and autoantibodies in PBC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 28. October 15-16. *
Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F 1992 Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases. Arch. Pathol. Lab. Med. 116: 643-648.
Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ 2001 Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 120: 190-199. *
Jakobs R, Weickert U, Hartmann D, Riemann JF 2005 Interventional endoscopy for benign and malignant bile duct strictures. Z. Gastroenterol. 43: 295-303.
Jamidar P 2006 Bile duct brushings for the early detection of cholangiocarcinoma. J. Clin. Gastroenterol. 40: 279-280.
Jarnagin WR, Shoup M 2004 Surgical management of cholangiocarcinoma. Semin. Liver Dis. 24: 189-199.
Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT 2007 Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J. Natl. Cancer Inst. 99: 895-897. *
Jeyarajah DR, Klintmalm GB 1998 Is liver transplantation indicated for cholangiocarcinoma? J. Hepatobiliary Pancreat. Surg. 5: 48-51.
Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA 2005 Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J. Biol. Chem. 280: 22986-22992. *
Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y 2006 Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 44: 1025-1038. *
John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR 2006 Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig. Surg. 23: 319-324.
Johnson KJ, Olliff JF, Olliff SP 1998 The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br. J. Radiol. 71: 1279-1282. *
Jonas S, Benckert C, Thelen A, Lopez-Hanninen E, Rosch T, Neuhaus P 2008 Radical surgery for hilar cholangiocarcinoma. Eur. J. Surg. Oncol. 34: 263-271.
Jones BA, Gores GJ 1998 Hepatobiliary malignancy. Clin. Liver Dis. 2: 437-449, xi-xii.
Joyce AM, Kochman ML 2005 Update on biliary endoscopy. Curr. Opin. Gastroenterol. 21: 354-358.
Jun SY, Kim JS, Yu E 2002 Primary sclerosing cholangitis - a report of two liver explants. Korean J. Pathol. 36: 420-424. *
Jung Y, McCall SJ, Li YX, Diehl AM 2007 Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology 45: 1091-1096. *
Kadry Z, Mullhaupt B, Renner EL, Bauerfeind P, Schanz U, Pestalozzi BC, Studer G, Zinkernagel R, Clavien PA 2003 Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76: 1003-1006.
Kahaleh M, Mishra R, Shami VM, Northup PG, Berg CL, Bashlor P, Jones P, Ellen K, Weiss GR, Brenin CM, Kurth BE, Rich TA, Adams RB, Yeaton P 2008 Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin. Gastroenterol. Hepatol. 6: 290-297.
Kaido T, Imamura M 2005 Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology 52: 725-727.
Kaieda M, Hamada N, Ishizaki N, Nakamura N, Kadono J, Fukueda M, Sakata R, Higashi M, Kitajima S, Yonezawa A 2002 A case of segmental primary sclerosing cholangitis associated with early cholangiocarcinoma--a review of the Japanese literature. Nippon Shokakibyo Gakkai Zasshi 99: 307-312.
Karlsen TH, Schrumpf E, Boberg KM 2007 Genetic epidemiology of primary sclerosing cholangitis. World J. Gastroenterol. 13: 5421-5431. *
Kawanishi S, Hiraku Y, Pinlaor S, Ma N 2006 Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387: 365-372.
Kaya M, de Groen PC, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, Haddock MG, Lindor KD 2001 Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am. J. Gastroenterol. 96: 1164-1169. *
Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, Tage-Jensen U, Dahlerup JF 2000 Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Ugeskr. Laeger. 162: 782-785.
Khalili K, Metser U, Wilson SR 2003 Hilar biliary obstruction: preliminary results with Levovist-enhanced sonography. AJR Am. J. Roentgenol. 180: 687-693. *
Khan SA, Davidson BR, Goldin R, Pereira S, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H 2003 GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHOLANGIOCARCINOMA - CONSENSUS DOCUMENT. (http://www.basl.org.uk/cholan.pdf). *
Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H; British Society of Gastroenterology 2003 Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl. 6: VI1-VI9.. *
Khan SA, Jane Cox I, Thillainayagam AV, Bansi DS, Thomas HC, Taylor-Robinson SD 2005 Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur. J. Gastroenterol. Hepatol. 17: 733-738.
Khan SA, Taylor-Robinson SD, Carmichael PL, Habib N, Lemoine NR, Thomas HC 2006 Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Int. J. Oncol. 28: 1269-1277. *
Kianmanesh R, Scaringi S, Castel B, Flamant Y, Msika S 2007 Precancerous lesions of the gallbladder. J. Chir. (Paris) 144: 278-286.
Kim HJ, Lee SK, Kim MH, Son JM, Lee SS, Park JS, Seo DW, Min YI 2002 Cystic fibrosis transmembrane conductance regulators (CFTR) in biliary epithelium of patients with hepatolithiasis. Dig. Dis. Sci. 47: 1758-1765. *
Kim JH, Kim TK, Eun HW, Byun JY, Lee MG, Ha HK, Auh YH 2006 CT findings of cholangiocarcinoma associated with recurrent pyogenic cholangitis. AJR Am. J. Roentgenol. 187: 1571-1577. *
Kim MJ, Kim JH, Lim JS, Oh YT, Chung JJ, Choi JS, Lee WJ, Kim KW 2004 Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20: 612-621.
Kinoshita H, Tanimura H, Uchiyama K, Tani M, Onishi H, Yamaue H 2002 Prognostic factors of intrahepatic cholangiocarcinoma after surgical treatment. Oncol. Rep. 9: 97-101. *
Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, Sebo TJ, Therneau TM, Gores GJ, Groen PC, Baron TH, Levy MJ, Halling KC, Roberts LR 2004 A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am. J. Gastroenterol. 99: 1675-1681. *
Kitano Y, Matsumoto K, Chisaka K, Imazawa M, Takahashi K, Nakade Y, Okada M, Aso K, Yokoyama K, Yamamoto M, Yoshie M, Ogawa K, Haneda M 2007 An autopsy case of autoimmune pancreatitis. JOP 8: 621-627. *
Kitiyakara T, Chapman RW 2008 Chemoprevention and screening in primary sclerosing cholangitis. Postgrad. Med. J. 84: 228-237.
Klompmaker IJ, Haagsma EB, Verwer R, Jansen PL, Sloofe MJ 1996 Primary sclerosing cholangitis and liver transplantation. Scand. J. Gastroenterol. Suppl. 218: 98-102.
Klump B, Hsieh CJ, Dette S, Holzmann K, Kiebetalich R, Jung M, Sinn U, Ortner M, Porschen R, Gregor M 2003 Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin. Cancer Res. 9: 1773-1778. *
Knechtle SJ, D'Alessandro AM, Harms BA, Pirsch JD, Belzer FO, Kalayoglu M 1995 Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 118: 615-619.
Ko KH, Kim NK, Yim DJ, Hong SP, Park PW, Rim KS, Kim S, Hwang SG 2006 Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res. 26: 4229-4233.
Kobayashi H, Hosotani R, Imai Y, Wada K, Kajiwara T 2005 Primary sclerosing cholangitis in which differential diagnosis from gallbladder carcinoma was difficult. J. Hepatobiliary Pancreat. Surg. 12: 151-154. *
Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S 2007 FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13: 902-911. *
Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ 2005 Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128: 2054-2065. *
Kobuke T, Tazuma S, Hyogo H, Chayama K 2006 A ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig. Dis. Sci. 51: 1650-1657. *
Kochhar R, Goenka MK, Das K, Nagi B, Bhasin DK, Chawla YK, Vaiphei K, Singh K, Dilawari JB 1996 Primary sclerosing cholangitis: an experience from India. J. Gastroenterol. Hepatol. 11: 429-433.
Kodama M, Murakami K, Okimoto T, Takayama A, Shiota S, Yasaka S, Otsu S, Ono M, Yoshiiwa A, Fujioka T 2007 Sclerosing cholangitis with autoimmune pancreatitis which resembles cholangiocarcinoma. Nippon Naika Gakkai Zasshi 96: 2525-2528.
Kohler TR, Debas H, Crames M, Strandness DE Jr 1990 Pancreaticoduodenectomy and the celiac artery compression syndrome. Ann. Vasc. Surg. 4: 77-80.
Kojima T, Shimura T, Takahashi M, Haga N, Hashimoto S, Fukuda T, Kuwano H 2004 A localized primary sclerosing cholangitis preoperatively diagnosed as hilar cholangiocarcinoma; report of a case. Hepatogastroenterology 51: 961-963.
Kolmannskog F, Aakhus T, Fausa O, Schrumpf E, Ritland S, Gjone E, Elgjo K 1981 Cholangiographic findings in ulcerative colitis. Acta Radiol. Diagn. (Stockh.) 22: 151-157.
Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T 2008 Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47: 888-896. *
Kongtawelert P, Tangkijvanich P, Ong-Chai S, Poovorawan Y 2003 Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma. World J. Gastroenterol. 9: 2178-2181. *
Korner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC 2006 Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J. Hepatol. 45: 825-835. *
Kornfeld D, Ekbom A, Ihre T 1997 Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand. J. Gastroenterol. 32: 1042-1045.
Kotei CN, Baddeley H, Salmon PR 1979 The role of endoscopic retrograde cholangiography in the diagnosis and management of patients with primary sclerosing cholangitis. Clin. Radiol. 30: 445-450.
Kubicka S, Kuhnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, Manns M, Meier PN 2001 K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 48: 403-408. *
Kubo S, Uenishi T, Yamamoto S, Hai S, Yamamoto T, Ogawa M, Takemura S, Shuto T, Tanaka H, Yamazaki O, Hirohashi K, Kinoshita H 2004 Clinicopathologic characteristics of small intrahepatic cholangiocarcinomas of mass-forming type. Hepatol. Res. 29: 223-227.
Kulaksiz H, Schlenker T, Rost D, Stiehl A, Volkmann M, Lehnert T, Cetin Y, Stremmel W 2004 Guanylin regulates chloride secretion in the human gallbladder via the bile fluid. Gastroenterology 126: 732-740. *
Kulkarni PB, Beatty E Jr 1977 Cholangiocarcinoma associated with biliary cirrhosis due to congenital biliary atresia. Am. J. Dis. Child. 131: 442-444.
Kullavanijaya P, Tangkijvanich P, Poovorawan Y 1999 Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J. Trop. Med. Public Health 30: 96-105.
Kumagi T, Alswat K, Hirschfield GM, Heathcote J 2008 New insights into autoimmune liver diseases. Hepatol. Res. May 6 [Epub ahead of print]. *
Kuroki T, Fukuda K, Tajima Y, Matsuzaki S, Kitajima T, Furui J, Kanematsu T 2005 Parapapillary choledochoduodenal fistula associated with cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 12: 143-146.
Kuroki T, Fukuda K, Yamanouchi K, Kitajima T, Matsuzaki S, Tajima Y, Furui J, Kanematsu T 2002 Helicobacter pylori accelerates the biliary epithelial cell proliferation activity in hepatolithiasis. Hepatogastroenterology 49: 648-651.
Kuroki T, Tajima Y, Kanematsu T 2005 Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J. Hepatobiliary Pancreat. Surg. 12: 463-466.
Laerm A, Helmbold P, Goldberg M, Dammann R, Holzhausen HJ, Ballhausen WG 2007 Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system. J. Hepatol. 46: 89-97. *
Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE 2005 erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129: 2047-2057. *
Lal A, Okonkwo A, Schindler S, De Frias D, Nayar R 2004 Role of biliary brush cytology in primary sclerosing cholangitis. Acta Cytol. 48: 9-12.
Lamarca S, Farinella M 1977 Primary sclerosing cholangitis. Arch. Sci. Med. (Torino) 134: 219-233.
Langer F, V Wasielewski R, Kreipe HH 2006 The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas. Pathologe 27: 244-250.
Langwieler TE, Kim JS, Mann O, Thonke F, Knoefel WT, Rogiers X, Izbicki JR 2004 Management of an unclear bile duct stenosis. Surg. Endosc. 18: 717-718.
LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH 2006 Primary sclerosing cholangitis: summary of a workshop. Hepatology 44: 746-764. *
Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA 1996 Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J. Clin. Invest. 98: 1313-1323. *
Layfield LJ, Cramer H 2005 Primary sclerosing cholangitis as a cause of false positive bile duct brushing cytology: report of two cases. Diagn. Cytopathol. 32: 119-124. *
Lazaridis KN 2003 Primary sclerosing cholangitis. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 43. September 12 - 13. *
Lazaridis KN 2008 Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 47: 8-10.
Lazaridis KN, Gores GJ 2005 Cholangiocarcinoma. Gastroenterology 128: 1655-1667. *
Lazaridis KN, Gores GJ 2006 Primary sclerosing cholangitis and cholangiocarcinoma. Semin. Liver Dis. 26: 42-51. *
Lazaridis KN, LaRusso NF 2003 Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220. *
Leclerc JC, Cannard L, Lefevre F, Debelle L, Beot S, Boccaccini H, Bazin C, Regent D 2001 Imaging of the intrahepatic biliary tree with thick slice MR cholangiography. J. Radiol. 82: 151-160.
Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS 2006 Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am. J. Clin. Oncol. 29: 127-131.
Lee KT, Liu TS 2001 Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas. Dig. Dis. Sci. 46: 2166-2172. *
Lee S 2004 Gallstones: how do we translate an old story into future therapy? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3. *
Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, Choi DL, Joo SH, Jeon JY, Chu CW, Moon DB, Min PC, Koh KS, Han SH, Park SH, Choi GT, Hwang KS, Lee EJ, Chung YH, Lee YS, Lee HJ, Kim MH, Lee SK, Suh DJ, Kim JJ, Sung KB 2002 Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J. Surg. 25: 277-284.
Lee SO 2008 Physiologic and pathologic experimental models for studying cholangiocytes. Korean J. Hepatol. 14: 139-149.
Lee TY, Chen YL, Chang HC, Chan CP, Kuo SJ 2007 Outcomes of hepatectomy for hepatolithiasis. World J. Surg. 31: 479-482. *
Lee WJ, Lim HK, Jang KM, Kim SH, Lee SJ, Lim JH, Choo IW 2001 Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics 21: 97-116. *
Lee YM 2002 Motion - patients with primary sclerosing cholangitis should undergo early liver transplantation: arguments for the motion. Can. J. Gastroenterol. 16: 697-699.
Lee YM, Kim DJ 2001 Primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 4: 469-477.
Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, Chantawibul S, Tepaksorn P 2006 Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J. Gastroenterol. 12: 4195-4198. *
Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U 2007 Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J. Trop. Med. Public Health 38: 881-885.
Lefkowitch JH 2003 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 19: 185-193.
Lefkowitch JH 2007 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231.
Lefkowitch JH 2004 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 20: 188-197.
Lempinen M, Isoniemi H, Makisalo H, Nordin A, Halme L, Arola J, Hockerstedt K, Stenman UH 2007 Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J. Hepatol. 47: 677-683. *
Lengyel G, Tulassay Z 2005 Possible treatment modalities of primary sclerosing cholangitis. Orv. Hetil. 146: 2479-2483.
Levy BF, Nisar A, Karanjia ND 2006 Cholangiocarcinoma, renal cell carcinoma and parathyroid adenoma found synchronously in a patient on long-term methotrexate. HPB (Oxford) 8: 151-153. *
Levy C, Lindor KD 2003 Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37. *
Levy C, Lindor KD 2003 Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103.
Levy C, Lindor KD 2006 Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin. Liver Dis. 26: 22-30. *
Levy C, Lymp J, Angulo P, Gores GJ, LaRusso N, Lindor KD 2005 The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50: 1734-1740. *
Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC 2007 Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am. J. Surg. Pathol. 31: 907-913.
Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N 2003 Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant. Proc. 35: 2995-2997. *
Lie-A-Ling M, Bakker CT, Deurholt T, Hoekstra R, Wesseling JG, Afford SC, Bosma PJ 2006 Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. J. Hepatol. 44: 126-133. *
Lillemoe KD, Pitt HA, Cameron JL 1988 Sclerosing cholangitis. Adv. Surg. 21: 65-92.
Lillemoe KD, Pitt HA, Cameron JL 1990 Primary sclerosing cholangitis. Surg. Clin. North Am. 70: 1381-1402.
Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T 2008 Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 68: 553-560. *
Limpaiboon T, Tapdara S, Jearanaikoon P, Sripa B, Bhudhisawasdi V 2006 Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World J. Gastroenterol. 12: 4377-4382. *
Lin TT, Yeh CT, Wu CS, Liaw YF 1995 Detection and partial sequence analysis of Helicobacter pylori DNA in the bile samples. Dig. Dis. Sci. 40: 2214-2219.
Lindberg B, Arnelo U, Bergquist A, Thorne A, Hjerpe A, Granqvist S, Hansson LO, Tribukait B, Persson B, Broome U 2002 Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 34: 909-916.
Linder S, Soderlund C 2001 Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer. Hepatogastroenterology 48: 387-392.
Lindner P, Norrby J, Olausson M, Rizell M, Cahlin C, Friman S 2003 Survival after liver transplantation for cholangiocarcinoma has increased during the last decade. Transplant. Proc. 35: 811-812. *
Lindor KD 2006 Ursodeoxycholic acid for the treatment of PSC. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 85-86. *
Liu XF, Zhu SG, Zhang H, Xu Z, Su HL, Li SJ, Zhou XT 2006 The methylation status of the TMS1/ASC gene in cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat. Dis. Int. 5: 449-453. *
Lohse AW 2006 Is small duct PSC a separate disease? Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 9. *
Lopez MJ, Lee YM 2005 Primary sclerosing cholangitis and primary biliary cirrhosis. The American College of Gastroenterology (http://www.acg.gi.org/patients/gihealth/pdf/sclerosing.pdf). *
Lopez RR Jr, Cosenza CA, Lois J, Hoffman AL, Sher LS, Noguchi H, Pan SH, McMonigle M 2001 Long-term results of metallic stents for benign biliary strictures. Arch. Surg. 136: 664-669. *
Maaouni S, Benaddi L, Kabbaj N, Errabih I, Alhamany Z, Benaissa A 2006 Krukenberg tumor: rare metastasis of hilar cholangiocarcinoma. Presse Med. 35: 1181-1184.
Mabrut JY, Partensky C, Jaeck D, Oussoultzoglou E, Baulieux J, Boillot O, Lerut J, de Ville de Goyet J, Hubert C, Otte JB, Audet M, Ducerf C, Gigot JF 2007 Congenital intrahepatic bile duct dilatation is a potentially curable disease: long-term results of a multi-institutional study. Ann. Surg. 246: 236-245.
MacCarty RL, LaRusso NF, May GR, Bender CE, Wiesner RH, King JE, Coffey RJ 1985 Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology 156: 43-46. *
MacFaul GR, Chapman RW 2004 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 20: 275-280.
MacFaul GR, Chapman RW 2005 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 21: 348-353.
Macfaul GR, Chapman RW 2006 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 22: 288-293.
Macken E, Drijkoningen M, Van Aken E, Van Steenbergen W 2000 Brush cytology of ductal strictures during ERCP. Acta Gastroenterol. Belg. 63: 254-259.
Maeda H 1998 Carcinogenesis via microbial infection. Gan To Kagaku Ryoho 25: 1474-1485.
Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM 2003 Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J. Hepatol. 38: 615-622. *
Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, LaRusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR, Monte SM 2004 Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect. Prev. 28: 313-318.
Maggs JR, Chapman RW 2007 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 23: 310-316.
Maggs JR, Chapman RW 2008 An update on primary sclerosing cholangitis. Curr. Opin. Gastroenterol. 24: 377-383.
Maheshwari A, Yoo HY, Thuluvath PJ 2004 Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am. J. Gastroenterol. 99: 538-542. *
Maier KP 2006 Natural course of primary sclerosing cholangitis (PSC). Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 5. *
Majoie CB, Smits NJ, Phoa SS, Reeders JW, Jansen PL 1995 Primary sclerosing cholangitis: sonographic findings. Abdom. Imaging 20: 109-112.
Malhi H, Gores GJ 2006 Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 45: 856-867. *
Malhi H, Gores GJ 2006 Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment. Pharmacol. Ther. 23: 1287-1296. *
Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY 2005 Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 25: 962-966. *
Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P 2004 Magnetic resonance imaging of cholangiocarcinoma. Semin. Liver Dis. 24: 155-164.
Mansfield JC, Griffin SM, Wadehra V, Matthewson K 1997 A prospective evaluation of cytology from biliary strictures. Gut 40: 671-677. *
Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ 2007 Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl. 13: 1372-1381.
Margalit M, Elinav H, Goldin E, Ilan Y 2003 Cholangiocarcinoma in primary sclerosing cholangitis: "chronicle of a death foretold"? Harefuah. 142: 421-425.
Margalit M, Elinav H, Ilan Y, Shalit M 2004 Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J. Gastroenterol. Hepatol. 19: 1338-1342. *
Marienfeld C, Yamagiwa Y, Ueno Y, Chiasson V, Brooks L, Meng F, Patel T 2004 Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology 127: 1787-1797. *
Martin R, Jarnagin W 2003 Intrahepatic cholangiocarcinoma. Current management. Minerva. Chir. 58: 469-478.
Martins EB, Chapman RW 2000 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 16: 444-449.
Martins EB, Chapman RW 1999 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 15: 436.
Martins EB, Fleming KA, Garrido MC, Hine KR, Chapman RW 1994 Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 107: 537-542.
Marzioni M, Fava G, Benedetti A 2006 Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J. Gastroenterol. 12: 3471-3480. *
Matsumoto T, Ajiki T, Matsumoto I, Tominaga M, Hori H, Mita Y, Fujita T, Fujino Y, Suzuki Y, Ku Y, Kuroda Y 2006 Intrahepatic segmental primary sclerosing cholangitis: report of a case. Surg. Today 36: 638-641. *
Mazhar D, Stebbing J, Bower M 2006 Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol. 2: 509-514.
McGlynn KA, Tarone RE, El-Serag HB 2006 A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev. 15: 1198-1203. *
McLean GK, Ring EJ, Freiman DB 1982 Therapeutic alternatives in the treatment of intrahepatic biliary obstruction. Radiology 145: 289-295. *
McLean L, Patel T 2006 Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int. 26: 1047-1053. *
McLoughlin M, Enns R 2008 Endoscopy in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 10: 177-185.
Meade CJ, Birke F, Metcalfe S, Watson C, Jamieson N, Neild G 1994 Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation. J. Lipid Mediat. Cell Signal. 9: 205-215.
Meier PN, Manns MP 2001 Medical and endoscopic treatment in primary sclerosing cholangitis. Best Pract. Res. Clin. Gastroenterol. 15: 657-666. *
Melum E, Karlsen TH, Bergquist A, Schrumpf E, Boberg KM 2008 An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 103: 1045. *
Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA 2008 Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47: 90-96.
Mendez-Sanchez N, Zamora-Valdes D, Vasquez-Fernandez F, Uribe M 2007 Hepatocellular carcinoma in Hispanics. Ann. Hepatol. 6: 279-280. *
Meng F, Yamagiwa Y, Ueno Y, Patel T 2006 Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J. Hepatol. 44: 1055-1065. *
Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN 2008 Mimics of cholangiocarcinoma: spectrum of disease. Radiographics 28: 1115-1129.
Metairie S, Lucidi V, Castaing D 2004 Intra-hepatic cholangiocarcinoma. J. Chir. (Paris) 141: 315-321.
Metz JM 2006 The role of radiation therapy in intrahepatic cholangiocarcinoma. Cancer J. 12: 102-104.
Meyenberger Ch, Fantin AC 2003 Biliary stents. Ther. Umsch. 60: 225-232.
Michaels A, Levy C 2008 The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61.
Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R 1991 Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 32: 1369-1373. *
Mitchell SA, Chapman RW 1997 Review article: the management of primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 11: 33-43.
Mitchell SA, Chapman RW 2000 Primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 18: 185-214.
Miyazaki M, Takada T, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Chijiiwa K, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F 2008 Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors. J. Hepatobiliary Pancreat. Surg. 15: 15-24.
Mobius C, Aust G, Wiedmann M, Wittekind C, Mossner J, Hauss J, Witzigmann H 2008 Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma. Anticancer Res. 28: 873-878.
Moff SL, Clark DP, Maitra A, Pandey A, Thuluvath PJ 2006 Utility of bile duct brushings for the early detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J. Clin. Gastroenterol. 40: 336-341.
Mohsine R, Blanchet MC, El Rassi Z, Ponchon T, Boillot O 2004 Liver transplantation for secondary sclerosing cholangitis following biliary surgery. Gastroenterol. Clin. Biol. 28: 181-184.
Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, Lee JD 2008 Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J. Gastroenterol. Hepatol. 23: 759-765. *
Moon DB, Lee SG 2004 Adult-to-adult living donor liver transplantation at the Asan Medical Center. Yonsei Med. J. 45: 1162-1168. *
Mori T, Sugiyama M, Atomi Y 2006 Gallstone disease: management of intrahepatic stones. Best Pract. Res. Clin. Gastroenterol. 20: 1117-1137.
Morris-Stiff G, Bhati C, Olliff S, Hubscher S, Gunson B, Mayer D, Mirza D, Buckels J, Bramhall SR 2008 Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig. Surg. 25: 126-132.
Moseley RH 2007 Liver and biliary tract disorders. Curr. Opin. Gastroenterol. 23: 217-220.
Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL 2008 N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod. Pathol. Jul 11 [Epub ahead of print].
Mott JL, Gores GJ 2007 Targeting IL-6 in cholangiocarcinoma therapy. Am. J. Gastroenterol. 102: 2171-2172. *
Moxon DR, Hong K, Brown RD, Venu RP 2003 Selective intrahepatic ductal cannulation during ERCP with a sphincterotome. Gastrointest. Endosc. 57: 738-743. *
Murray MD, Burton FR, Di Bisceglie AM 2007 Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J. Clin. Gastroenterol. 41: 115-117.
Nakanuma Y, Sasaki M, Ikeda H, Sato Y, Zen Y, Kosaka K, Harada K 2008 Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol. Res. 38: 325-334. *
Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, Pitt HA 1996 Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am. J. Surg. 171: 147-152.
Narayanan Menon KV, Wiesner RH 1999 Etiology and natural history of primary sclerosing cholangitis. J. Hepatobiliary Pancreat. Surg. 6: 343-351.
Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL 1995 Liver transplantation for sclerosing cholangitis. Hepatology 22: 451-457.
Nehls O, Gregor M, Klump B 2004 Serum and bile markers for cholangiocarcinoma. Semin. Liver Dis. 24: 139-154.
Neuberger J 2004 Liver transplantation for autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83. *
Neuberger J 2003 Primary sclerosing cholangitis: indications for transplantation and recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 93-94. October 15-16. *
Neuberger J 2003 Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121.
Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr 1993 Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin. Proc. 68: 874-879.
Nikolaidis NL, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, Vassiliadis T, Eugenidis NP 2005 Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig. Dis. Sci. 50: 324-326. *
Nilsson HO, Mulchandani R, Tranberg KG, Wadstrom T 2001 Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology 120: 323-324. *
Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S 2008 Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J. Hepatol. 49: 207-216.
Nissen NN, Cavazzoni E, Tran TT, Poordad FP 2004 Emerging role of transplantation for primary liver cancers. Cancer J. 10: 88-96.
No authors listed 2007 The evolving use of positron emission tomography (PET) for diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl. 13: 622-623.
Noack KB, Speer T 1997 Investigation of the patient with abnormal liver function tests. Baillieres Clin. Gastroenterol. 11: 83-95.
Nonomura A, Minato H, Shimizu K, Kadoya M, Matsui O 1997 Hepatic hilar inflammatory pseudotumor mimicking cholangiocarcinoma with cholangitis and phlebitis--a variant of primary sclerosing cholangitis? Pathol. Res. Pract. 193: 519-525.
Nuernberg D, Ignee A, Dietrich CF 2007 Ultrasound in gastroenterology. Biliopancreatic system. Med. Klin. (Munich) 102: 112-126.
Nunez Martinez O, Clemente Ricote G, Garcia Monzon C 2003 Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases. Med. Clin. (Barc.) 121: 743-748.
O'Grady JG 2000 Treatment options for other hepatic malignancies. Liver Transpl. 6: S23-S29. *
Obama K, Satoh S, Hamamoto R, Sakai Y, Nakamura Y, Furukawa Y 2008 Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells. Clin. Cancer Res. 14: 1333-1339.
Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, Satoh S, Nakamura Y, Furukawa Y 2005 Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41: 1339-1348. *
Ohshima H, Bartsch H 1994 Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 305: 253-264.
Oikarinen H 2001 Imaging of biliary carcinoma, fistula and primary sclerosing cholangitis and percutaneous metallic stenting in malignant biliary obstruction. Department of Diagnostic Radiology, University of Oulu, Oulu Finland ISBN 951-42-5917-3 (http://herkules.oulu.fi/isbn9514259173/isbn9514259173.pdf). *
Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G 1996 Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur. J. Gastroenterol. Hepatol. 8: 685-691.
Oldakowska-Jedynak U, Nowak M, Mucha K, Foroncewicz B, Nyckowski P, Zieniewicz K, Ziarkiewicz-Wroblewska B, Patkowski W, Gornicka B, Paczkowska A, Michalowicz B, Pilecki T, Pawlak J, Krawczyk M, Paczek L 2006 Recurrence of primary sclerosing cholangitis in patients after liver transplantation. Transplant. Proc. 38: 240-243. *
Olnes MJ, Erlich R 2004 A review and update on cholangiocarcinoma. Oncology 66: 167-179.
Olsson R 2003 Small duct primary sclerosing cholangitis: a separate disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 62. October 15-16. *
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsoy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzen H, Ung KA, Eriksson A, Loof L, Prytz H, Marschall HU, Broome U 2005 High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a five year multicenter randomised controlled study. Gastroenterology 129: 1464-1472. *
Ortner MA 2004 Photodynamic therapy in cholangiocarcinomas. Best Pract. Res. Clin. Gastroenterol. 18: 147-154.
Ortner MA, Dorta G 2006 Technology insight: photodynamic therapy for cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 459-467. *
Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J, Lochs H 2003 Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125: 1355-1363. *
Otto G 2007 Diagnostic and surgical approaches in hilar cholangiocarcinoma. Int. J. Colorectal Dis. 22: 101-108. *
Oya H, Sato Y, Yamamoto S, Takeishi T, Kobayashi T, Hatakeyama K 2004 Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: a case report. Transplant. Proc. 36: 2297-2298. *
Padilla D, Cubo T, Pardo R, Molina JM, Hernandez J 2004 Late development of cholangiocarcinoma after hepaticojejunostomy due to ampullary carcinoma. Gut 53: 472-473. *
Paik WH, Park YS, Hwang JH, Lee SH, Yoon CJ, Kang SG, Lee JK, Ryu JK, Kim YT, Yoon YB 2008 Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest. Endosc. Jul 25 [Epub ahead of print].
Palmer KR, Cotton PB, Chapman M 1984 Pancreatogram in cholestasis. Gut 25: 424-427. *
Panes J, Bordas JM, Bruguera M, Cortes M, Rodes J 1985 Localized sclerosing cholangitis? Endoscopy 17: 121-122.
Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M 2004 Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57. *
Papachristou GI, Wu T, Marsh W, Plevy SE 2004 Inflammatory pseudotumor of the liver associated with Crohn's disease. J. Clin. Gastroenterol. 38: 818-822.
Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS, Lee JH, Kim KA, Kim AY, Kim PN, Lee MG, Ha HK 2004 Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 233: 234-240. *
Parlak E, Kuran SO, Disibeyaz S, Cicek B, Oguz D, Sahin B 2004 Endoscopic treatment of primary sclerosing cholangitis. Turk. J. Gastroenterol. 15: 144-148. *
Pascher A, Jonas S, Neuhaus P 2003 Intrahepatic cholangiocarcinoma: indication for transplantation. J. Hepatobiliary Pancreat. Surg. 10: 282-287.
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ 2000 The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 204-207. *
Patel T 2002 Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2: 10. *
Patel T, Singh P 2007 Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr. Opin. Gastroenterol. 23: 317-323.
Pavlov CS 2006 Histopathology of primary sclerosing cholangitis (PSC). Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 6-7. *
Pawlik TM, Olbrecht VA, Pitt HA, Gleisner AL, Choti MA, Schulick RD, Cameron JL 2008 Primary sclerosing cholangitis: role of extrahepatic biliary resection. J. Am. Coll. Surg. 206: 822-830. *
Perdue DG, Cass OW, Milla C, Dunitz J, Jessurun J, Sharp HL, Schwarzenberg SJ 2007 Hepatolithiasis and cholangiocarcinoma in cystic fibrosis: a case series and review of the literature. Dig. Dis. Sci. 52: 2638-2642. *
Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, Clavien PA 2006 Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol. 45: 43-50. *
Pilleul F, Courbiere M, Henry L, Scoazec JY, Valette PJ 2004 Etiology of biliary stenosis at MR cholangiography: correlation with pathology findings. J. Radiol. 85: 25-30.
Pippert H, Gross-Fengels W, Siemens P, Kruse T 1991 A rare constellation of findings: bile duct cancer, ulcerative colitis, deep venous thrombosis of the leg. Aktuelle. Radiol. 1: 259-261.
Plata-Munoz JJ, Hernandez-Ramirez D, Anthon FJ, Podgaetz E, Avila-Flores F, Chan C 2004 Polysplenia syndrome in the adult patient. Case report with review of the literature. Ann. Hepatol. 3: 114-117. *
Pokorny CS, McCaughan GW, Gallagher ND, Selby WS 1992 Sclerosing cholangitis and biliary tract calculi--primary or secondary? Gut 33: 1376-1380. *
Ponsioen CI, Tytgat GN 1998 Primary sclerosing cholangitis: a clinical review. Am. J. Gastroenterol. 93: 515-523. *
Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, Reitsma JB, Heisterkamp SH, Tytgat GN 2002 Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51: 562-566. *
Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP 2005 Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16. *
Poupon R, Chazouilleres O, Poupon RE 2000 Chronic cholestatic diseases. J. Hepatol. 32: S129-S140.
Prall RT, Lindor KD, Wiesner RH, LaRusso NF 2000 Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103.
Prawan A, Kukongviriyapan V, Tassaneeyakul W, Pairojkul C, Bhudhisawasdi V 2005 Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur. J. Cancer Prev. 14: 245-250.
Principe A, Ercolani G, Bassi F, Paolucci U, Raspadori A, Turi P, Beltempo P, Grazi GL, Cavallari A 2003 Diagnostic dilemmas in biliary strictures mimicking cholangiocarcinoma. Hepatogastroenterology 50: 1246-1249.
Prytz H, Keiding S, Bjornsson E, Broome U, Almer S, Castedal M, Munk OL 2006 Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44: 1572-1580. *
Rahn NH 3rd, Koehler RE, Weyman PJ, Truss CD, Sagel SS, Stanley RJ 1983 CT appearance of sclerosing cholangitis. AJR Am. J. Roentgenol. 141: 549-552. *
Rai R, Manas D, Rose J 2005 Radiofrequency ablation of recurrent cholangiocarcinoma after orthotopic liver transplantation - a case report. World J. Gastroenterol. 11: 612-613. *
Raj V, Lichtenstein DR 1999 Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28: 491-513.
Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R 1995 Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108: 865-869. *
Ramalho FS, Ramalho LN, Della Porta L, Zucoloto S 2006 Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1276-1280. *
Ramos Rubio E 2007 Radical surgery for hilar cholangiocarcinoma (Klatskin tumor). Cir. Esp. 82: 11-15.
Rana SS, Bhasin DK, Nanda M, Singh K 2007 Parasitic infestations of the biliary tract. Curr. Gastroenterol. Rep. 9: 156-164.
Rasmussen HH, Fallingborg J, Mortensen PB, Freund L, Tage-Jensen U, Kruse V, Rasmussen SN 1992 Primary sclerosing cholangitis in patients with ulcerative colitis. Scand. J. Gastroenterol. 27: 732-736.
Rasmussen HH, Fallingborg JF, Mortensen PB, Freund LG, Tage-Jensen U, Kruse V, Rasmussen SN 1994 Sclerosing cholangitis and ulcerative colitis. Regional prevalence. Ugeskr. Laeger. 156: 179-182.
Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM 2005 Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242: 451-458. *
Reddy SB, Patel T 2006 Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 8: 30-37.
Rehman SU, Amin MF, Hussain MA 2005 Management of HILAR malignant biliary strictures. J. Pak. Med. Assoc. 55: 339-342.
Reichel C, Meier-Abt PJ 1997 Cholestatic liver diseases. Ther. Umsch. 54: 639-644.
Ridruejo Saez R, Jimenez Bartolome B 2006 Infected cholangiocarcinoma. An. Med. Interna. 23: 335-337.
Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R 1996 p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 38: 265-268. *
Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Garcia-Valdelcasas JC, Lopez P, Gomez M, de Vicente E, Loinaz C, Santoyo J, Casanova D, Bernardos A, Fernandez JA, Marin C, Ramirez P, Bueno FS, Jaurrieta E, Parrilla P 2003 Liver transplantation for hilar cholangiocarcinoma: Spanish experience. Transplant. Proc. 35: 1821-1822. *
Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Valdecasas JC, Lopez P, Gomez M, de Vicente E, Loinaz C, Santoyo J, Fleitas M, Bernardos A, Llado L, Ramirez P, Bueno FS, Jaurrieta E, Parrilla P 2004 Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann. Surg. 239: 265-271. *
Rocken C, Pross M, Brucks U, Ridwelski K, Roessner A 2000 Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). Arch. Pathol. Lab. Med. 124: 1704-1706. *
Rodriguez HJ, Bass NM 2003 Primary sclerosing cholangitis. Semin. Gastrointest. Dis. 14: 189-198.
Roman RM, Feranchak AP, Salter KD, Wang Y, Fitz JG 1999 Endogenous ATP release regulates Cl- secretion in cultured human and rat biliary epithelial cells. Am. J. Physiol. 276: G1391-G1400. *
Rosen CB, Nagorney DM 1991 Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin. Liver Dis. 11: 26-30.
Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF 1991 Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann. Surg. 213: 21-25. *
Roskams T 2006 Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25: 3818-3822. *
Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A 2007 The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur. J. Gastroenterol. Hepatol. 19: 487-491.
Safioleas MC 2005 A new technique for the palliative treatment of high bile duct cancer. Hepatogastroenterology 52: 378-380.
Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H 2005 Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today 35: 548-552.
Saich R, Chapman R 2008 Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J. Gastroenterol. 14: 331-337. *
Sali A, McQuillan T, Read A, Kune G 1991 Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases. J. Cancer Res. Clin. Oncol. 117: 503-504.
Sandhu BS, Luketic VA 2006 Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849. *
Sandhu DS, Shire AM, Roberts LR 2008 Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int. 28: 12-27. *
Sasaki M, Tsuneyama K, Nakanuma Y 2003 Aberrant expression of trefoil factor family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. Lab. Invest. 83: 1403-1413.
Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC 2006 Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology 44: 658-666. *
Scheimann AO, Strautnieks SS, Knisely AS, Byrne JA, Thompson RJ, Finegold MJ 2007 Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. J. Pediatr. 150: 556-559. *
Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW, Baba HA 2007 GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 9: 159-165. *
Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kolmannskog F 1994 Risk factors in primary sclerosing cholangitis. J. Hepatol. 21: 1061-1066.
Schrumpf E, Boberg KM 2002 Endoscopic treatment for primary sclerosing cholangitis? J. Hepatol. 36: 278-279. *
Schrumpf E, Boberg KM 2004 Standard treatment of PSC and overlap AIH/PSC. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 71. *
Schrumpf E, Fausa O, Aadland E, Elgjo K, Kolmannskog F 1990 Primary sclerosing cholangitis and inflammatory bowel disease. Tidsskr. Nor. Laegeforen. 110: 1212-1216.
Schrumpf E, Fausa O, Kolmannskog F, Elgjo K, Ritland S, Gjone E 1982 Sclerosing cholangitis in ulcerative colitis. A follow-up study. Scand. J. Gastroenterol. 17: 33-39.
Schrumpf E, Jorgensen KK, Boberg KM 2006 Primary sclerosing cholangitis, inflammatory bowel disease and treatment options. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 15-16. *
Schulick RD 2008 Primary sclerosing cholangitis detection of cancer in strictures. J. Gastrointest. Surg. 12: 420-422. *
Schumacher G, Bechstein WO, Kling N, Lobeck H, Hintze R, Neuhaus P 1997 Bile duct carcinoma in an adenoma in the anastomotic area after hepaticojejunostomy--a case report. Z. Gastroenterol. 35: 1081-1086.
Sears RJ, Duckworth CW, Decaestecker C, Bourgeois N, Ledent T, Deviere J, Salmon I, Kiss R, Yeaton P 1998 Image cytometry as a discriminatory tool for cytologic specimens obtained by endoscopic retrograde cholangiopancreatography. Cancer 84: 119-126. *
Sekido H, Takeda K, Morioka D, Kubota T, Tanaka K, Endo I, Nagahori K, Togo S, Shimada H 1999 Liver transplantation for primary sclerosing cholangitis. J. Hepatobiliary Pancreat. Surg. 6: 373-376.
Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Wongkham S 2007 Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer 109: 2497-2505. *
Shah RJ, Langer DA, Antillon MR, Chen YK 2006 Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. Clin. Gastroenterol. Hepatol. 4: 219-225.
Shaib Y, El-Serag HB 2004 The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24: 115-125.
Shaib YH, Davila JA, McGlynn K, El-Serag HB 2004 Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol. 40: 472-477. *
Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA 2005 Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128: 620-626. *
Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM 2007 Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am. J. Gastroenterol. 102: 1016-1021. *
Sherlock S 2000 Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin. Liver Dis. 4: 97-113.
Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S 2004 MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39: 220-229. *
Shimokura GH, McGill JM, Schlenker T, Fitz JG 1995 Ursodeoxycholate increases cytosolic calcium concentration and activates Cl- currents in a biliary cell line. Gastroenterology 109: 965-972. *
Shimonishi T, Sasaki M, Nakanuma Y 2000 Precancerous lesions of intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 7: 542-550.
Shoda J, Tanaka N, Osuga T 2003 Hepatolithiasis--epidemiology and pathogenesis update. Front. Biosci. 8: e398-e409.